HCM
CELU icon

Highbridge Capital Management’s Celularity CELU Stock Holding History

Highbridge Capital Management’s Portfolio CELU Stock Details CELU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-154,135
Closed -$15.7M – 324
2021
Q2 		$15.7M Buy
154,135
+143,815
+1,394% +$14.6M 0.44% 72
2021
Q1 		$1.04M Buy
+10,320
New +$1.06M 0.04% 138

Other funds holding CELU

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Highbridge Capital Management's CELU Position: Q3 2021 in Review

Highbridge Capital Management sold out of Celularity (CELU) in Q3 2021, closing a stake of 154,135 shares — an estimated $15.7M sold.

Highbridge Capital Management first reported a position in CELU in Q1 2021 and held it in 2 quarters. The position peaked at $15.7M in Q2 2021. 21 funds tracked by Wall St. Rank hold CELU as of Q3 2021.

  • Highbridge Capital Management reported no remaining Celularity position as of Q3 2021 after selling out during the quarter.
  • Highbridge Capital Management sold 154,135 Celularity shares in Q3 2021, an estimated $15.7M.
  • Highbridge Capital Management first reported a position in Celularity in Q1 2021 and held it in 2 quarters.
  • Highbridge Capital Management's Celularity position peaked at $15.7M in Q2 2021.
  • 21 funds tracked by Wall St. Rank held Celularity as of Q3 2021.

Based on Highbridge Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.